SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13426)10/8/2004 1:47:42 PM
From: Biomaven  Read Replies (2) | Respond to of 52153
 
I wonder whether the fallout from the Vioxx debacle isn't going to be fairly prolonged. It might cause some investors to question the whole risk/reward characteristics of pharma, and by extension biotech. Certainly to the extent the FDA becomes more cautious that hurts pharma and biotech, in the short run at least.

The Chiron vaccine problems also don't help. And if Lilly loses the Zyprexa patent case then confidence could be really shaken.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News